nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—T—bone cancer	0.0619	0.156	CbGpPWpGaD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—CITED2—bone cancer	0.0542	0.137	CbGpPWpGaD
Vidarabine—Apprehension—Cisplatin—bone cancer	0.043	0.0742	CcSEcCtD
Vidarabine—ADK—Nucleotide metabolism—NT5C3A—bone cancer	0.041	0.104	CbGpPWpGaD
Vidarabine—ADA—Nucleotide metabolism—NT5C3A—bone cancer	0.0279	0.0704	CbGpPWpGaD
Vidarabine—Coronary artery disease—Cisplatin—bone cancer	0.0209	0.036	CcSEcCtD
Vidarabine—Glucosamine—MMP9—bone cancer	0.0204	0.853	CrCbGaD
Vidarabine—Electrocardiogram ST segment depression—Epirubicin—bone cancer	0.0187	0.0322	CcSEcCtD
Vidarabine—Electrocardiogram ST segment depression—Doxorubicin—bone cancer	0.0173	0.0298	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—TNFRSF11A—bone cancer	0.0147	0.037	CbGpPWpGaD
Vidarabine—Taste metallic—Methotrexate—bone cancer	0.0142	0.0245	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—WT1—bone cancer	0.0135	0.034	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—bone cancer	0.012	0.0304	CbGpPWpGaD
Vidarabine—Supraventricular extrasystoles—Epirubicin—bone cancer	0.0114	0.0196	CcSEcCtD
Vidarabine—Supraventricular extrasystoles—Doxorubicin—bone cancer	0.0105	0.0181	CcSEcCtD
Vidarabine—Sinus tachycardia—Epirubicin—bone cancer	0.0105	0.0181	CcSEcCtD
Vidarabine—Sinus tachycardia—Doxorubicin—bone cancer	0.00973	0.0168	CcSEcCtD
Vidarabine—Pain—Carboplatin—bone cancer	0.00858	0.0148	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—TNFRSF11A—bone cancer	0.00843	0.0213	CbGpPWpGaD
Vidarabine—ADORA2A—GPCRs, Other—GRM1—bone cancer	0.00835	0.0211	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—BRCA2—bone cancer	0.00795	0.0201	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—MOGS—bone cancer	0.00778	0.0196	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—MDM2—bone cancer	0.00662	0.0167	CbGpPWpGaD
Vidarabine—Nasal congestion—Cisplatin—bone cancer	0.00657	0.0113	CcSEcCtD
Vidarabine—Burning sensation—Methotrexate—bone cancer	0.00651	0.0112	CcSEcCtD
Vidarabine—Hyperventilation—Epirubicin—bone cancer	0.00615	0.0106	CcSEcCtD
Vidarabine—Cerebrovascular accident—Cisplatin—bone cancer	0.00611	0.0105	CcSEcCtD
Vidarabine—Burning sensation—Epirubicin—bone cancer	0.0061	0.0105	CcSEcCtD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—MDM2—bone cancer	0.00592	0.0149	CbGpPWpGaD
Vidarabine—ADORA2A—GPCRs, Other—SMO—bone cancer	0.00588	0.0148	CbGpPWpGaD
Vidarabine—Ventricular arrhythmia—Epirubicin—bone cancer	0.00572	0.00987	CcSEcCtD
Vidarabine—Hyperventilation—Doxorubicin—bone cancer	0.00569	0.00982	CcSEcCtD
Vidarabine—Burning sensation—Doxorubicin—bone cancer	0.00564	0.00973	CcSEcCtD
Vidarabine—Scotoma—Epirubicin—bone cancer	0.00558	0.00962	CcSEcCtD
Vidarabine—Apnoea—Methotrexate—bone cancer	0.00534	0.00921	CcSEcCtD
Vidarabine—Ventricular arrhythmia—Doxorubicin—bone cancer	0.00529	0.00913	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—KIT—bone cancer	0.00528	0.0133	CbGpPWpGaD
Vidarabine—Scotoma—Doxorubicin—bone cancer	0.00516	0.0089	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—RB1—bone cancer	0.00512	0.0129	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—GNA11—bone cancer	0.00497	0.0125	CbGpPWpGaD
Vidarabine—Abdominal discomfort—Cisplatin—bone cancer	0.00496	0.00855	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—EZH2—bone cancer	0.00495	0.0125	CbGpPWpGaD
Vidarabine—Ventricular extrasystoles—Epirubicin—bone cancer	0.00469	0.00809	CcSEcCtD
Vidarabine—Respiratory failure—Methotrexate—bone cancer	0.00461	0.00795	CcSEcCtD
Vidarabine—Acute coronary syndrome—Cisplatin—bone cancer	0.00455	0.00784	CcSEcCtD
Vidarabine—Myocardial infarction—Cisplatin—bone cancer	0.00452	0.0078	CcSEcCtD
Vidarabine—ADK—Metabolism—NDUFA12—bone cancer	0.0045	0.0114	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—MDM2—bone cancer	0.00437	0.011	CbGpPWpGaD
Vidarabine—Atrioventricular block—Epirubicin—bone cancer	0.00437	0.00753	CcSEcCtD
Vidarabine—Ventricular extrasystoles—Doxorubicin—bone cancer	0.00434	0.00748	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—TUBB4B—bone cancer	0.00426	0.0108	CbGpPWpGaD
Vidarabine—Ventricular tachycardia—Epirubicin—bone cancer	0.00424	0.0073	CcSEcCtD
Vidarabine—Bradycardia—Cisplatin—bone cancer	0.00422	0.00727	CcSEcCtD
Vidarabine—Injection site reaction—Epirubicin—bone cancer	0.00421	0.00726	CcSEcCtD
Vidarabine—Atrioventricular block—Doxorubicin—bone cancer	0.00404	0.00697	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—PTGS2—bone cancer	0.00401	0.0101	CbGpPWpGaD
Vidarabine—Ventricular tachycardia—Doxorubicin—bone cancer	0.00392	0.00676	CcSEcCtD
Vidarabine—Injection site reaction—Doxorubicin—bone cancer	0.0039	0.00672	CcSEcCtD
Vidarabine—Tinnitus—Cisplatin—bone cancer	0.00386	0.00666	CcSEcCtD
Vidarabine—Cardiac disorder—Cisplatin—bone cancer	0.00384	0.00663	CcSEcCtD
Vidarabine—Flushing—Cisplatin—bone cancer	0.00384	0.00663	CcSEcCtD
Vidarabine—Mediastinal disorder—Cisplatin—bone cancer	0.00373	0.00644	CcSEcCtD
Vidarabine—ADK—Metabolism—NT5C3A—bone cancer	0.00373	0.00941	CbGpPWpGaD
Vidarabine—Arrhythmia—Cisplatin—bone cancer	0.0037	0.00638	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—TUBB2A—bone cancer	0.00368	0.00928	CbGpPWpGaD
Vidarabine—Cytarabine—CYP3A4—bone cancer	0.00351	0.147	CrCbGaD
Vidarabine—Vision blurred—Cisplatin—bone cancer	0.0034	0.00586	CcSEcCtD
Vidarabine—Tremor—Cisplatin—bone cancer	0.00338	0.00583	CcSEcCtD
Vidarabine—Cerebrovascular accident—Methotrexate—bone cancer	0.00335	0.00578	CcSEcCtD
Vidarabine—Cardiac failure—Epirubicin—bone cancer	0.00315	0.00543	CcSEcCtD
Vidarabine—Cerebrovascular accident—Epirubicin—bone cancer	0.00314	0.00541	CcSEcCtD
Vidarabine—Convulsion—Cisplatin—bone cancer	0.00312	0.00539	CcSEcCtD
Vidarabine—Mood swings—Methotrexate—bone cancer	0.00311	0.00537	CcSEcCtD
Vidarabine—Anxiety—Cisplatin—bone cancer	0.00306	0.00527	CcSEcCtD
Vidarabine—ADA—Metabolism—NDUFA12—bone cancer	0.00306	0.00772	CbGpPWpGaD
Vidarabine—Discomfort—Cisplatin—bone cancer	0.00303	0.00523	CcSEcCtD
Vidarabine—Affect lability—Epirubicin—bone cancer	0.00303	0.00522	CcSEcCtD
Vidarabine—Anaphylactic shock—Cisplatin—bone cancer	0.00294	0.00507	CcSEcCtD
Vidarabine—Cardiac arrest—Epirubicin—bone cancer	0.00292	0.00504	CcSEcCtD
Vidarabine—Cardiac failure—Doxorubicin—bone cancer	0.00291	0.00503	CcSEcCtD
Vidarabine—Mood swings—Epirubicin—bone cancer	0.00291	0.00502	CcSEcCtD
Vidarabine—Cerebrovascular accident—Doxorubicin—bone cancer	0.0029	0.00501	CcSEcCtD
Vidarabine—Tachycardia—Cisplatin—bone cancer	0.00287	0.00495	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—GNA11—bone cancer	0.00285	0.0072	CbGpPWpGaD
Vidarabine—Hyperhidrosis—Cisplatin—bone cancer	0.00284	0.00491	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—EZH2—bone cancer	0.00284	0.00717	CbGpPWpGaD
Vidarabine—Affect lability—Doxorubicin—bone cancer	0.0028	0.00483	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—CDK4—bone cancer	0.00279	0.00705	CbGpPWpGaD
Vidarabine—Hypotension—Cisplatin—bone cancer	0.00275	0.00474	CcSEcCtD
Vidarabine—ADORA2A—GPCR ligand binding—GRM4—bone cancer	0.00273	0.00688	CbGpPWpGaD
Vidarabine—Abdominal discomfort—Methotrexate—bone cancer	0.00272	0.00469	CcSEcCtD
Vidarabine—Cardiac arrest—Doxorubicin—bone cancer	0.0027	0.00466	CcSEcCtD
Vidarabine—Mood swings—Doxorubicin—bone cancer	0.00269	0.00465	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00268	0.00462	CcSEcCtD
Vidarabine—Paraesthesia—Cisplatin—bone cancer	0.00264	0.00456	CcSEcCtD
Vidarabine—Dyspnoea—Cisplatin—bone cancer	0.00262	0.00452	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—ATF1—bone cancer	0.0026	0.00656	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—EIF2S1—bone cancer	0.00257	0.00648	CbGpPWpGaD
Vidarabine—ADA—Metabolism—NT5C3A—bone cancer	0.00253	0.00639	CbGpPWpGaD
Vidarabine—Drowsiness—Methotrexate—bone cancer	0.00253	0.00437	CcSEcCtD
Vidarabine—Pain—Cisplatin—bone cancer	0.00252	0.00434	CcSEcCtD
Vidarabine—Pollakiuria—Epirubicin—bone cancer	0.00245	0.00423	CcSEcCtD
Vidarabine—Sweating—Methotrexate—bone cancer	0.00243	0.00419	CcSEcCtD
Vidarabine—Drowsiness—Epirubicin—bone cancer	0.00237	0.00409	CcSEcCtD
Vidarabine—ADORA2A—GPCR ligand binding—GRM1—bone cancer	0.00237	0.00597	CbGpPWpGaD
Vidarabine—Sweating—Epirubicin—bone cancer	0.00227	0.00392	CcSEcCtD
Vidarabine—Pollakiuria—Doxorubicin—bone cancer	0.00227	0.00392	CcSEcCtD
Vidarabine—Drowsiness—Doxorubicin—bone cancer	0.00219	0.00378	CcSEcCtD
Vidarabine—Hypersensitivity—Cisplatin—bone cancer	0.00217	0.00374	CcSEcCtD
Vidarabine—Bradycardia—Epirubicin—bone cancer	0.00217	0.00373	CcSEcCtD
Vidarabine—Tinnitus—Methotrexate—bone cancer	0.00212	0.00365	CcSEcCtD
Vidarabine—Hypoaesthesia—Epirubicin—bone cancer	0.00212	0.00365	CcSEcCtD
Vidarabine—Asthenia—Cisplatin—bone cancer	0.00211	0.00364	CcSEcCtD
Vidarabine—Cardiac disorder—Methotrexate—bone cancer	0.00211	0.00364	CcSEcCtD
Vidarabine—Sweating—Doxorubicin—bone cancer	0.0021	0.00362	CcSEcCtD
Vidarabine—Mediastinal disorder—Methotrexate—bone cancer	0.00205	0.00353	CcSEcCtD
Vidarabine—Bradycardia—Doxorubicin—bone cancer	0.002	0.00345	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—ATF1—bone cancer	0.002	0.00505	CbGpPWpGaD
Vidarabine—Tinnitus—Epirubicin—bone cancer	0.00198	0.00342	CcSEcCtD
Vidarabine—Flushing—Epirubicin—bone cancer	0.00197	0.0034	CcSEcCtD
Vidarabine—Cardiac disorder—Epirubicin—bone cancer	0.00197	0.0034	CcSEcCtD
Vidarabine—Hypoaesthesia—Doxorubicin—bone cancer	0.00196	0.00338	CcSEcCtD
Vidarabine—Dysgeusia—Methotrexate—bone cancer	0.00194	0.00334	CcSEcCtD
Vidarabine—Mediastinal disorder—Epirubicin—bone cancer	0.00192	0.00331	CcSEcCtD
Vidarabine—Back pain—Methotrexate—bone cancer	0.00191	0.0033	CcSEcCtD
Vidarabine—Arrhythmia—Epirubicin—bone cancer	0.0019	0.00328	CcSEcCtD
Vidarabine—Vomiting—Cisplatin—bone cancer	0.00187	0.00323	CcSEcCtD
Vidarabine—Vision blurred—Methotrexate—bone cancer	0.00186	0.00322	CcSEcCtD
Vidarabine—Rash—Cisplatin—bone cancer	0.00186	0.0032	CcSEcCtD
Vidarabine—Dermatitis—Cisplatin—bone cancer	0.00185	0.0032	CcSEcCtD
Vidarabine—Tinnitus—Doxorubicin—bone cancer	0.00183	0.00316	CcSEcCtD
Vidarabine—Cardiac disorder—Doxorubicin—bone cancer	0.00183	0.00315	CcSEcCtD
Vidarabine—Flushing—Doxorubicin—bone cancer	0.00183	0.00315	CcSEcCtD
Vidarabine—Tension—Epirubicin—bone cancer	0.00182	0.00313	CcSEcCtD
Vidarabine—Dysgeusia—Epirubicin—bone cancer	0.00181	0.00313	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—JUN—bone cancer	0.0018	0.00454	CbGpPWpGaD
Vidarabine—Nervousness—Epirubicin—bone cancer	0.0018	0.0031	CcSEcCtD
Vidarabine—Back pain—Epirubicin—bone cancer	0.00179	0.00309	CcSEcCtD
Vidarabine—Mediastinal disorder—Doxorubicin—bone cancer	0.00177	0.00306	CcSEcCtD
Vidarabine—Arrhythmia—Doxorubicin—bone cancer	0.00176	0.00303	CcSEcCtD
Vidarabine—Nausea—Cisplatin—bone cancer	0.00175	0.00301	CcSEcCtD
Vidarabine—Vision blurred—Epirubicin—bone cancer	0.00174	0.00301	CcSEcCtD
Vidarabine—Cough—Methotrexate—bone cancer	0.00173	0.00298	CcSEcCtD
Vidarabine—Convulsion—Methotrexate—bone cancer	0.00171	0.00296	CcSEcCtD
Vidarabine—Agitation—Epirubicin—bone cancer	0.0017	0.00293	CcSEcCtD
Vidarabine—Chest pain—Methotrexate—bone cancer	0.00168	0.0029	CcSEcCtD
Vidarabine—Tension—Doxorubicin—bone cancer	0.00168	0.0029	CcSEcCtD
Vidarabine—Dysgeusia—Doxorubicin—bone cancer	0.00168	0.00289	CcSEcCtD
Vidarabine—ADORA2A—GPCR ligand binding—SMO—bone cancer	0.00167	0.00421	CbGpPWpGaD
Vidarabine—Discomfort—Methotrexate—bone cancer	0.00166	0.00287	CcSEcCtD
Vidarabine—Nervousness—Doxorubicin—bone cancer	0.00166	0.00287	CcSEcCtD
Vidarabine—Syncope—Epirubicin—bone cancer	0.00166	0.00286	CcSEcCtD
Vidarabine—Back pain—Doxorubicin—bone cancer	0.00166	0.00286	CcSEcCtD
Vidarabine—Palpitations—Epirubicin—bone cancer	0.00164	0.00282	CcSEcCtD
Vidarabine—ADK—Metabolism—ENO2—bone cancer	0.00163	0.00412	CbGpPWpGaD
Vidarabine—Loss of consciousness—Epirubicin—bone cancer	0.00163	0.00281	CcSEcCtD
Vidarabine—Cough—Epirubicin—bone cancer	0.00162	0.00279	CcSEcCtD
Vidarabine—Anaphylactic shock—Methotrexate—bone cancer	0.00161	0.00278	CcSEcCtD
Vidarabine—Vision blurred—Doxorubicin—bone cancer	0.00161	0.00278	CcSEcCtD
Vidarabine—Convulsion—Epirubicin—bone cancer	0.0016	0.00277	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—CDK4—bone cancer	0.0016	0.00405	CbGpPWpGaD
Vidarabine—Hypertension—Epirubicin—bone cancer	0.0016	0.00276	CcSEcCtD
Vidarabine—Chest pain—Epirubicin—bone cancer	0.00158	0.00272	CcSEcCtD
Vidarabine—Agitation—Doxorubicin—bone cancer	0.00157	0.00271	CcSEcCtD
Vidarabine—Anxiety—Epirubicin—bone cancer	0.00157	0.00271	CcSEcCtD
Vidarabine—Hyperhidrosis—Methotrexate—bone cancer	0.00156	0.00269	CcSEcCtD
Vidarabine—Discomfort—Epirubicin—bone cancer	0.00156	0.00269	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—RGS1—bone cancer	0.00154	0.00389	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—GRM4—bone cancer	0.00154	0.00389	CbGpPWpGaD
Vidarabine—Dry mouth—Epirubicin—bone cancer	0.00154	0.00266	CcSEcCtD
Vidarabine—Syncope—Doxorubicin—bone cancer	0.00154	0.00265	CcSEcCtD
Vidarabine—ADK—Metabolism—DHFR—bone cancer	0.00151	0.00382	CbGpPWpGaD
Vidarabine—Palpitations—Doxorubicin—bone cancer	0.00151	0.00261	CcSEcCtD
Vidarabine—Anaphylactic shock—Epirubicin—bone cancer	0.00151	0.00261	CcSEcCtD
Vidarabine—Hypotension—Methotrexate—bone cancer	0.00151	0.0026	CcSEcCtD
Vidarabine—Loss of consciousness—Doxorubicin—bone cancer	0.00151	0.0026	CcSEcCtD
Vidarabine—Cough—Doxorubicin—bone cancer	0.00149	0.00258	CcSEcCtD
Vidarabine—Shock—Epirubicin—bone cancer	0.00149	0.00256	CcSEcCtD
Vidarabine—Convulsion—Doxorubicin—bone cancer	0.00148	0.00256	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KIT—bone cancer	0.00148	0.00373	CbGpPWpGaD
Vidarabine—Hypertension—Doxorubicin—bone cancer	0.00148	0.00255	CcSEcCtD
Vidarabine—Tachycardia—Epirubicin—bone cancer	0.00147	0.00254	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00147	0.00254	CcSEcCtD
Vidarabine—Hyperhidrosis—Epirubicin—bone cancer	0.00146	0.00252	CcSEcCtD
Vidarabine—Chest pain—Doxorubicin—bone cancer	0.00146	0.00252	CcSEcCtD
Vidarabine—Anxiety—Doxorubicin—bone cancer	0.00145	0.00251	CcSEcCtD
Vidarabine—Paraesthesia—Methotrexate—bone cancer	0.00145	0.0025	CcSEcCtD
Vidarabine—Discomfort—Doxorubicin—bone cancer	0.00144	0.00249	CcSEcCtD
Vidarabine—Dyspnoea—Methotrexate—bone cancer	0.00144	0.00248	CcSEcCtD
Vidarabine—Somnolence—Methotrexate—bone cancer	0.00144	0.00248	CcSEcCtD
Vidarabine—Dry mouth—Doxorubicin—bone cancer	0.00143	0.00246	CcSEcCtD
Vidarabine—ADK—Metabolism—GNA11—bone cancer	0.00142	0.00357	CbGpPWpGaD
Vidarabine—Hypotension—Epirubicin—bone cancer	0.00141	0.00243	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—GRM4—bone cancer	0.0014	0.00353	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—RGS1—bone cancer	0.0014	0.00353	CbGpPWpGaD
Vidarabine—Anaphylactic shock—Doxorubicin—bone cancer	0.0014	0.00241	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	0.00139	0.00351	CbGpPWpGaD
Vidarabine—Pain—Methotrexate—bone cancer	0.00138	0.00238	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00138	0.00237	CcSEcCtD
Vidarabine—Shock—Doxorubicin—bone cancer	0.00138	0.00237	CcSEcCtD
Vidarabine—Tachycardia—Doxorubicin—bone cancer	0.00136	0.00235	CcSEcCtD
Vidarabine—Paraesthesia—Epirubicin—bone cancer	0.00136	0.00234	CcSEcCtD
Vidarabine—Hyperhidrosis—Doxorubicin—bone cancer	0.00135	0.00233	CcSEcCtD
Vidarabine—Dyspnoea—Epirubicin—bone cancer	0.00135	0.00232	CcSEcCtD
Vidarabine—Somnolence—Epirubicin—bone cancer	0.00134	0.00232	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—GRM1—bone cancer	0.00134	0.00337	CbGpPWpGaD
Vidarabine—Hypotension—Doxorubicin—bone cancer	0.00131	0.00225	CcSEcCtD
Vidarabine—Pain—Epirubicin—bone cancer	0.00129	0.00223	CcSEcCtD
Vidarabine—ADK—Metabolism—CYP3A4—bone cancer	0.00128	0.00324	CbGpPWpGaD
Vidarabine—Urticaria—Methotrexate—bone cancer	0.00128	0.00221	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00127	0.0022	CcSEcCtD
Vidarabine—Paraesthesia—Doxorubicin—bone cancer	0.00126	0.00217	CcSEcCtD
Vidarabine—Dyspnoea—Doxorubicin—bone cancer	0.00125	0.00215	CcSEcCtD
Vidarabine—Somnolence—Doxorubicin—bone cancer	0.00124	0.00214	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—GRM1—bone cancer	0.00121	0.00306	CbGpPWpGaD
Vidarabine—Urticaria—Epirubicin—bone cancer	0.0012	0.00207	CcSEcCtD
Vidarabine—Pain—Doxorubicin—bone cancer	0.0012	0.00206	CcSEcCtD
Vidarabine—Hypersensitivity—Methotrexate—bone cancer	0.00119	0.00205	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—TP53—bone cancer	0.00119	0.003	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	0.00117	0.00294	CbGpPWpGaD
Vidarabine—Asthenia—Methotrexate—bone cancer	0.00116	0.002	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—KIT—bone cancer	0.00114	0.00287	CbGpPWpGaD
Vidarabine—Hypersensitivity—Epirubicin—bone cancer	0.00111	0.00192	CcSEcCtD
Vidarabine—Urticaria—Doxorubicin—bone cancer	0.00111	0.00192	CcSEcCtD
Vidarabine—ADA—Metabolism—ENO2—bone cancer	0.00111	0.0028	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GSTP1—bone cancer	0.0011	0.00277	CbGpPWpGaD
Vidarabine—Asthenia—Epirubicin—bone cancer	0.00108	0.00187	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—BRAF—bone cancer	0.00107	0.0027	CbGpPWpGaD
Vidarabine—Dizziness—Methotrexate—bone cancer	0.00107	0.00184	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—MMP2—bone cancer	0.00105	0.00265	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—JUN—bone cancer	0.00103	0.00261	CbGpPWpGaD
Vidarabine—Hypersensitivity—Doxorubicin—bone cancer	0.00103	0.00178	CcSEcCtD
Vidarabine—ADA—Metabolism—DHFR—bone cancer	0.00103	0.0026	CbGpPWpGaD
Vidarabine—Vomiting—Methotrexate—bone cancer	0.00103	0.00177	CcSEcCtD
Vidarabine—Rash—Methotrexate—bone cancer	0.00102	0.00176	CcSEcCtD
Vidarabine—Dermatitis—Methotrexate—bone cancer	0.00102	0.00175	CcSEcCtD
Vidarabine—Headache—Methotrexate—bone cancer	0.00101	0.00174	CcSEcCtD
Vidarabine—Asthenia—Doxorubicin—bone cancer	0.001	0.00173	CcSEcCtD
Vidarabine—Dizziness—Epirubicin—bone cancer	0.000999	0.00172	CcSEcCtD
Vidarabine—ADA—Metabolism—GNA11—bone cancer	0.000962	0.00243	CbGpPWpGaD
Vidarabine—Vomiting—Epirubicin—bone cancer	0.000961	0.00166	CcSEcCtD
Vidarabine—Nausea—Methotrexate—bone cancer	0.000959	0.00165	CcSEcCtD
Vidarabine—Rash—Epirubicin—bone cancer	0.000953	0.00164	CcSEcCtD
Vidarabine—Dermatitis—Epirubicin—bone cancer	0.000952	0.00164	CcSEcCtD
Vidarabine—Headache—Epirubicin—bone cancer	0.000947	0.00163	CcSEcCtD
Vidarabine—Dizziness—Doxorubicin—bone cancer	0.000925	0.00159	CcSEcCtD
Vidarabine—Nausea—Epirubicin—bone cancer	0.000898	0.00155	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—MDM2—bone cancer	0.000896	0.00226	CbGpPWpGaD
Vidarabine—Vomiting—Doxorubicin—bone cancer	0.000889	0.00153	CcSEcCtD
Vidarabine—Rash—Doxorubicin—bone cancer	0.000882	0.00152	CcSEcCtD
Vidarabine—Dermatitis—Doxorubicin—bone cancer	0.000881	0.00152	CcSEcCtD
Vidarabine—Headache—Doxorubicin—bone cancer	0.000876	0.00151	CcSEcCtD
Vidarabine—ADA—Metabolism—CYP3A4—bone cancer	0.000872	0.0022	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—GNA11—bone cancer	0.000861	0.00217	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—SMO—bone cancer	0.000855	0.00216	CbGpPWpGaD
Vidarabine—Nausea—Doxorubicin—bone cancer	0.00083	0.00143	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—RGS1—bone cancer	0.000827	0.00209	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GRM4—bone cancer	0.000827	0.00209	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	0.000797	0.00201	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—GNA11—bone cancer	0.000782	0.00197	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—IL3—bone cancer	0.000781	0.00197	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTP1—bone cancer	0.000746	0.00188	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GRM1—bone cancer	0.000717	0.00181	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL3—bone cancer	0.000709	0.00179	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—TP53—bone cancer	0.000682	0.00172	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—EGFR—bone cancer	0.000613	0.00155	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PTGS2—bone cancer	0.000569	0.00143	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SMO—bone cancer	0.000505	0.00128	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GNA11—bone cancer	0.000462	0.00117	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ATF1—bone cancer	0.00043	0.00108	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL3—bone cancer	0.000419	0.00106	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PTGS2—bone cancer	0.000387	0.000975	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TGFBR2—bone cancer	0.000358	0.000904	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IGF1R—bone cancer	0.000337	0.000851	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KIT—bone cancer	0.000244	0.000617	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—BRAF—bone cancer	0.00023	0.00058	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—EGFR—bone cancer	0.000223	0.000562	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MDM2—bone cancer	0.000193	0.000486	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—JUN—bone cancer	0.000167	0.000422	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MMP9—bone cancer	0.000163	0.000411	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EGFR—bone cancer	0.000132	0.000332	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TP53—bone cancer	0.00011	0.000279	CbGpPWpGaD
